Comparison of effectiveness using Curcuma Longa Linn versus omeprazole in treatment of Functional Dyspepsia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20171218001

Enrollment

Registered

2017-12-18

Start date

2018-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

TREATMENT OF FUNCTIONAL DYSPEPSIA CURCUMA LONGA LINN OMEPRAZOLE QUALITY OF LIFE TREATMENT OF FUNCTIONAL DYSPEPSIA CURCUMA LONGA LINN OMEPRAZOLE QUALITY OF LIFE

Interventions

CURCUMIN,OMEPRAZOLE,PLACEBO

Experimental Drug,Active Comparator Drug,Sham Comparator Drug

CURCUMIN GROUP,OMEPRAZOLE GROUP,PLACEBO GROUP

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: FUNCTIONAL DYSPEPSIA BY ROME IV CRITERIA

Exclusion criteria

Exclusion criteria: HELICOBACTOR PYLORI INFECTION JAUNDICE ANEMIA CHRONIC KIDNEY DISEASE STAGE MORE THAN 4 ASA USE PREGNANCY ALLERGIC TO CURCUMIN LONGA LINN

Design outcomes

Primary

Measure	Time frame
Effectiveness by mean of Change of SODA score 4 weeks after allocation SODA score	—

Secondary

Measure	Time frame
QUALITY OF LIFE 4 weeks after allocation EQ5D	—

Countries

THAILAND

Contacts

Public ContactKACHONSAK YONGWATANA

PHRAMONGKUTKLAO HOSPITAL

PLANCAKE86@HOTMAIL.COM0841003928

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026